华安证券给予三鑫医疗买入评级：2025H1盈利能力稳定，海外市场持续高增长

Group 1 - The core viewpoint of the report is that Huazhong Securities has given a "buy" rating for Sanxin Medical (300453.SZ) based on strong growth prospects in both domestic and overseas markets [2] - The overseas market is expected to maintain a high growth rate, with an estimated growth of approximately 67% in the first half of 2025 [2] - The core business of blood dialysis is projected to continue its rapid growth, with an expected year-on-year growth rate of about 20% in the first half of 2025 [2] - The company plans to issue convertible bonds worth 530 million yuan to support ongoing capacity expansion [2]